Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients
|
|
- Lindsay Hoover
- 5 years ago
- Views:
Transcription
1 (2004) 7, & 2004 Nature Publishing Group All rights reserved /04 $ Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients P Rodrigues 1, F Hering 1 & JC Campagnari 1 1 Beneficência Portuguesa Hospital of São Paulo and Santa Helena Hospital of São Paulo, São Paulo, SP, Brazil Introduction: Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with bone lysis by osteoclast proliferation, paralleling nearby bone deposition. The treatment options are palliative and have poor clinical response with short-lived improvement. We have studied the clinical effect of bisphosphonates (clodronate) in the treatment of skeletal complications from prostate cancer. Materials and Methods: In an open prospective study, 58 patients with hormonerefractory prostate cancer with bone metastases were assessed from November 2000 to September The mean age was 70.3 y (range: y). Bone scintigraphy, plain X-ray, assaying of prostate-specific antigen (PSA) and biochemical tests were requested before and following treatment. Patients were previously and subsequently assessed using the visual pain scale (0 10) and Karnofsky s index after the first and second intravenous (i.v.) infusions (administration of i.v. clodronate every 28 days) and every 4 6 months thereafter. Student s t-test was used for statistical analysis. Results: A total of 53 patients (91.4%) showed improvement after the first and/or second cycle, which persisted for at least 4 months (average 6.3 months). The averages on the visual pain scale improved from 7.4 (range: 2 8) to 2.4 (0 7) and on Karnofsky s index from 43 (32 58) to 73 (50 82). The radiological appearance of the metastases improved in 27 patients (46.5%) and there were few relapses (six patients; 10.3%). Conclusions: Clodronate was effective in the treatment of skeletal complications from prostate cancer. There was an objective response in 91.4% of treated patients, with a marked improvement in the subjective visual pain scale evaluation as well as on Karnofsky s index, with low side effects. (2004) 7, doi: /sj.pcan Published online 9 November 2004 Keywords: prostate carcinoma; prostate metastasis; bone metastasis, bisphosphonates; pain palliation Introduction The incidence of prostate carcinoma has greatly increased over the last decade and it is now the most Correspondence: P Rodrigues, Rua Maestro Cardim andar, Paraíso- São Paulo, SP, CEP , Brazil. paulortrodrigues@aol.com Received 9 December 2003; revised 15 May 2004; accepted 22 June 2004; published online 9 November 2004 common type of noncutaneous cancer found in men over 50 y. Today, even with all the efforts towards early detection, 20% of patients already present bone metastases at the time of diagnosing prostate cancer. Considering that about 30% of patients who receive treatment for localised prostate cancer present a relapse, the number of patients with advanced disease is significantly high. Most of such patients who are undergoing hormone treatment become refractory to hormonal management
2 after a time of months, despite the therapy, and 85 95% of them will present bone metastases and their complications such as pain, fractures and paralysis. 1,2 Patients with bone metastases have an average survival of 30 months, which is a very long time and requires therapies directed towards treating the pain from the metastases or the complications related to pathological fractures. 2 4 Bone metastases from prostate cancer are viewed via plain radiography as osteoblastic lesions. However, this concept is outdated, since it is known that lytic lesions are always present in the microenvironment and are caused by tumoral prostatic cells that interrupt normal bone remodelling through irregular stimulation of osteoclasts and osteoblasts. Following the formation of the lytic lesion, excessive deposition of lamellar bone in the lacunae takes place, thus giving rise to the osteoblastic appearance. This mechanism results in osteosclerosis, thereby increasing the bone volume and destroying the normal bone. 5,6 Bisphosphonates have been widely employed in treating bone metastases caused by breast cancer and multiple myeloma, with excellent results. They are potent inhibitors of both normal and pathological bone reabsorption, exerting a depressant effect on mature osteoclasts and inhibiting the stimulation of osteoblasts, thereby decreasing skeletal complications. 7 The present study has evaluated the clinical effect of bisphosphonates (clodronate) in patients with bone metastases due to hormone-refractory prostate adenocarcinoma. Materials and methods Between November 2000 and September 2003, 58 patients with bone pain due to metastases from advanced hormone-refractory prostate adenocarcinoma were prospectively evaluated and treated with clodronate in an open study. This study was preceded by a review of the literature and approval of the study protocol from the Ethics Committees of the hospitals involved. The patients mean age was 70.3 y (range: 51 87) and they presented progressive bone disease confirmed radiologically or by scintigraphy, or they presented increasing bone pain. Before these patients were enrolled on this treatment protocol, 16 had undergone orchiectomy. A total of 19 patients were using cyproterone acetate, 13 used LH-RH analogues, two used bicalutamide and eight use oestrogens. All the patients presented castrated levels of testosterone (o50 ng/dl). Mitoxantrone and corticoids were being administered to nine patients following hormonal blockade failure. Six patients were receiving estramustine phosphate, four used ketoconazole with corticoids and three used PC- SPES to control pain and disease progression, as measured by increasing prostate-specific antigen (PSA) or pain. A total of 38 patients were taking nonopioid analgesics due to pain at the time of enrolment. These medications were all suspended when the clinical or biochemical response ceased. Patients were considered to be hormone-refractory after three consecutive increases in PSA, despite the above-mentioned therapy, over 6 months of follow-up. After patients were enrolled, the various drugs they had been using were suspended and bisphosphonates were administered alone with no other analgesics. Further analgesic usage was carefully evaluated by the authors. Before the administration of the first clodronate dose, patients underwent skeletal mapping to record the quantity and location of metastases. Every point with hypercaptation highly suggestive of metastases was radiographed. Improvements seen via radiological imaging were subjectively evaluated by the authors on the basis of the intensity and quantity of metastasis seen on bone scintigraphy. Skeletal events necessitating radiotherapy for pain palliation of fracture treatment were deemed to be evidence of failure and/or progression. All patients were asked to estimate their pain on a visual pain scale from 0 to 10 (no pain to very strong pain), at every visit, and their general condition was assessed via Karnofsky s index. Patients were deemed responsive to clodronate if the visual pain scale diminished by more than five points, irrespective of the initial pain measurement. The patients were contacted every 14 days: either they revisited or they were called by telephone). After 4 6 months of treatment, the patients underwent bone scintigraphy again, for comparison with the initial result. Radiographs of metastasis locations were also taken. Monthly determinations of PSA, phosphatases, calcium, creatinine and transaminases were made, and hemograms with the erythrocyte sedimentation rate were produced. Clodronate was administered intravenously every 28 days at a dosage of 1500 mg (five vials of 300 mg diluted in 500 ml of saline solution infused over two hours). The procedure was carried out as at an outpatient basis without requiring admission to hospital. Following the infusion, the patient was released for his normal activities. For parametric and nonparametric statistical analysis of variations in the pain scale and Karnofsky s index, Student s t-test was used for comparing data before and during treatment. Results According to the visual pain scale, 53 patients (91. 4%) responded to treatment with intravenous bisphosphonate. The average value on the visual pain scale before treatment was 7.4 (range: 2 9) and after treatment it decreased to 2.4 (range: 0 7) (Table 1). Predominantly, osteoblastic lesions were observed in 46 cases (79.2%), while osteolytic lesions were observed in the remaining 12 cases (20.8%). A radiological improvement in the metastases was observed in 27 patients (46.5%) after the first 6 months. Osteoblastic patients showed a response in 47.8% of the cases (22 out of 46), while only 8.6% of the osteolytic lesions (five cases out of 12) presented radiological improvement (Table 2). The pelvic bones were the site most frequently affected by metastases (29.3%; 17 cases), followed by the lumbar column (15.5%; nine cases) and hips (5.1%; three cases). However, scattered lesions were the predominant type (50%; 29 cases). 351
3 352 Table 1 Improvement in pain according to visual scale after two cycles of bisphosphonate in 58 treated patients Pain scale level following clodronate administration Patients % Diminished Z5 points after treatment Diminished o5 points after treatment Without improvement Total with improvement Table 2 Improvement in radiological imaging in 27 responsive patients after treatment with clodronate Type N Radiological response according to the type of the lesion (% of whole group) Osteoblastic Osteolytic Total Table 4 Exclusively biochemical response in 14 patients with advanced hormone-refractory prostate cancer whose PSA was diminished after 6 months of treatment with intravenous clodronate Patient Before treatment After treatment Average Among the 53 responsive patients, the average Karnofsky s index score improved from 43 (range: 32 58) to 71 (range: 50 82) (Table 3). Four patients (6.8%) did not respond to clodronate and required opioids just after the first two intravenous administrations of clodronate. A total of 22 patients (37.9%) completely stopped using analgesics during the first 6 months of this protocol, while 24 (41.4%) controlled their pain with nonsteroidal nonopioid antiinflammatory drugs during these initial 6 months but exclusively after 2-months of analgesic-free period. Disease progression led to the use of narcotics by eight of the 25 patients who completed more than 24 months of follow-up. The patients completed an average of 8.8 cycles (range: 2 32) before progression became evident. The median PSA was 54 (mean: ; range ). The comparable PSA response before and after treatment did not show any trend, with only 14 cases (24.1%) presenting objective reduction that was not related to radiological response (not shown) (Table 4). There were minimal side effects. Four patients had mild digestive disorders and two had superficial phlebitis in the infused arm (Table 5). Discussion Bone metastases are the most frequent event in advanced prostate cancer. It is known that approximately 85% of patients who die from prostate carcinoma have skeletal Table 5 Side effects reported by 58 patients treated with clodronate for advanced hormone-refractory prostate cancer Type Patients % Superficial phlebitis Diarrhoea Slight digestive disorders Abdominal pain Total lesions and related complications such as pain, pathological fractures or spinal compression. 4 On the basis of clinical and experimental studies, it can be concluded that bone metastases in prostate and breast cancer have similar behaviour. Bisphosphonates are widely employed and accepted as an adjuvant treatment for breast cancer, with excellent clinical and radiological results. 6,8 Recent research has demonstrated that, both in multiple myeloma and in prostate or breast cancer, the key to the formation of lesions is increased osteoclastic activity that promotes bone lysis. Subsequently, there will be excessive and disordered deposition of sclerotic bone because of the increased osteoblastic activity (osteoblastosis). In prostate cancer, such deposition is what most often confers the radiological appearance of an osteoblastic lesion. 7 Cancerous cells detach from the prostate, reach the blood circulation and are attracted to bone by local and distant chemotactic factors inside bones. PSA, bone sialoprotein (BSP), thymidine phosphorylase (TP) and bone morphogenetic protein-6 (BMP6) share a biochemical specificity towards bone, thereby predisposing Table 3 Summary of data on 58 patients who underwent treatment with clodronate scored by Karnofsky s index Parameters No. of patients Before treatment After treatment Average on pain scale for patients with no response Average Karnofsky s index score for patients with no response (38 69) 60.4 (38 72) Average on pain scale for responsive patients Average Karnofsky s index score for responsive patients (32 58) 73.3 (50 82)
4 detached cells to land on fertile soil where metastasis can develop The release of local paracrine factors that promote the initial bone absorption is triggered by osteoclast activation, thereby initiating the lytic lesion. Factors that promote increased osteoblastic activity are subsequently released in anarchic patterns that allow excessive bone deposition over the initial lytic lesion. Bisphosphonates cause a decrease in osteoclast activity, thereby inhibiting bone lysis. They also cause decreased osteoblast activity, which prevents the hyperactivity among these cells (osteoblastosis) that would culminate in excessive bone formation. Direct cytotoxic action on the tumour has also been described, with the inhibition of angiogenesis and promotion of direct apoptosis of cancerous cells, in addition to inhibition of metalloproteases and cytokines. 1,6,8,11,12 Bisphosphonates can be divided into two large groups: aminobisphosphonates (NBPs: pamidronate, ibandronate, alendronate and zoledronate) and nonamino bisphosphonates (non-nbps: clodronate and etidronate). Differently from non-nbps, NBPs do not have a nitrogen atom in their formulation, which give them a different mechanism of action at the molecular level. While NBPs act inside cells, inhibiting the mevalonate cycle, non- NBPs act by promoting direct cytotoxicity towards osteoclasts and osteoblasts, thereby inducing apoptosis and inhibiting the ATP/ADP translocase enzyme. 13,14 The differences in pharmacological action between the groups determine their effects on the inflammatory process. Non-NBPs such as clodronate have anti-inflammatory action and antirheumatic activity, whereas this is not well established in NBPs. 14 Preclinical studies have demonstrated that osteolytic lesions always precede the abnormal bone deposition (osteoblastosis) that gives the osteoblastic appearance to the majority of metastatic skeletal lesions from prostate cancer. 7 It has been shown through biopsies of metastatic skeletal lesions that excessive bone absorption occurs at these sites, in the same way as it occurs in breast cancer. 6,7 The rationale for using bisphosphonates in the treatment of prostate cancer comes from studies that have demonstrated their beneficial effects in inhibiting the invasion of prostatic cancerous cells as well as their adherence to and lysis of bone matrix. As already mentioned, bisphosphonates have been used in the treatment of breast cancer and multiple myeloma since the early 1980s, with excellent clinical results. However, it was only at the beginning of the 1990s that the first studies using bisphosphonates in the treatment of prostate cancer appeared. 8,13 The first study using bisphosphonate in the treatment of prostate cancer was conducted with clodronate by Adami et al in In this study, 17 patients with osteoblastic metastases were treated by administering 300 mg of intravenous clodronate daily for 14 days and 3200 mg orally for a further 4 11 weeks. A significant improvement in 16 patients (94.1%) was observed, in relation to pain and Karnofsky s index, for 4 8 weeks. 14 Vorreuther 15 administered intravenous clodronate to 41 patients with skeletal lesions due to prostate cancer, at a dosage of 300 mg daily for 8 days, along with 1600 mg orally. It was observed that 20 patients (71%) presented significant reduction in pain as early as the first 3 5 days, with nine patients continuing to show response thereafter. Heidenreich et al 16 treated a larger group of 85 patients with skeletal complications due to metastatic prostate cancer. The dose was 300 mg of intravenous clodronate daily for 8 days and 1600 mg daily by oral route for maintenance. A response rate of 75% was observed in the group, with an improvement in Karnofsky s index from 45 to 70%, while 19 patients (22%) persistently showed no response. The studies mentioned above corroborate our results. The results from Adami et al 14 were reproduced in our study: more than 90% of our patients had a significant reduction in pain, with 49 patients improving by more than five points on the pain scale and an improvement in Karnofsky s index from 42% (range: 32 55%) to 71% (range: 50 82%) following intravenous treatment with clodronate. 14 In our study, we used intravenous clodronate in bolus at a dose of 1500 mg (five vials containing 300 mg), diluted in 500 ml of saline solution and applied over a 2-h period every 28 days, performed on an outpatient basis. Side effects were observed in only 10.3% of cases and these were mild and transitory drawbacks. They did not preclude further administration, as occurred in Vorreuther s series. 15 The intravenous route was chosen because previous studies 17 showed that the oral route was highly correlated with adverse gastrointestinal effects that led to reductions in the drug dose. Following intravenous administration, 70 80% of the active substance is cleared via the urine within 24 h. An additional advantage claimed for clodronate is precisely the possibility for oral usage, as demonstrated in clinical scenarios. 15,16,18 However, when Smith 19 used oral etidronate, he did not observe an improvement in patients in relation to the placebo group, possibly because the low absorption by this route became ineffective and failed to reproduce the improvement observed by others. In a more recent series, Dearnaley et al 17 also failed to show an improvement among 311 patients who were randomly assigned to oral clodronate (2080 mg/day) or a matching placebo group, after 59 months of follow-up. An average increase of 8.7 months in survival was observed in the group with the active drug. Patients who were free of symptomatic bone progression also showed a favourable trend in the group with the active drug, with a 21% reduction in bone metastasis. This did not, however, reach statistical significance or have an impact on the overall survival. This effect may be explained by the direct action that clodronate exerts over metastatic tumoral cells, as shown by others. 8,12 However, a deeper look into Dearnaley et al s 17 study reveals that it was composed of subjects with an average PSA of 5.0 ng/dl, while our series essentially consisted of more advanced cases (average PSA of 54), which may explain the lack of clinical response in Dearnaley s study. Moreover, the oral route (which has around 2% bioavailability) is associated with a marked effect from food intake on clodronate absorption, and this may favour the intravenous route when this drug is considered. This may also explain the pain control obtained in a randomised controlled trial that favoured intravenous pamidronate over oral clodronato. 20 The severity of the disease may be an important issue for debate when 353
5 354 studying the effect of bisphosphonates in the treatment of metastatic prostate cancer. Patient characteristics may influence the clinical response, as pointed out by Ernst et al, 21 who failed to show improvement in pain control after adjuvant clodronate vs mitoxantrone. He had an analgesic response (450% decrease in analgesic intake from baseline) in 33% out of 104 cases using clodronate and 30% in the placebo group. However the response rate was quite different when only the subgroup of patients with moderate pain was analysed, with a 58% response in the treated group and 26% in the placebo group. This revealed that the patients with high baseline pain were more prone to respond to bisphosphonates than the mild cases. The use of bisphosphonate in metastatic prostate cancer cases has been gaining wide attention from urologists, who have been tracking the results from breast cancer and myeloma, where its usage is largely accepted, established and consensual. 8 From this, a randomised multicentre clinical study using the new generation of bisphosphonates (zoledronic acid) showed statistically significant differences that favoured its use in comparison with placebo in preventing skeleton-related events after 15 months of follow-up, and with no impact on clinical disease progression, quality-of-life index or performance status. 22 In this study, the patients were comparable to ours (median PSA of 88.2 ng/dl), and the pain relief was dramatic in the first 6 months of administration. However, the pain relief did not reach statistical significance at 15 months, probably because the disease did not stop progressing. Pain control was not the primary assessment in this study as skeletal-related event (fractures) was, but its consistently verified effect had not been previously confirmed in a double-blind randomised trial. In conclusion, it can be seen that clodronate can dramatically reduce pain in advanced hormone-refractory prostate cancer patients, with prompt effects on pain, few side effects and a significant improvement in performance status, as measured by Karnofsky s index. References 1 Berruti A et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. JUrol2000; 164: Greenlee RT, Murray T, Bolden S. Cancer statistics, American Cancer Society, January/February 2000; 50: Parker SL, Tong T, Bolden S. Cancer statistics Cancer J Clin 1997; 47: Issacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: Smith Jr JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54: Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: Dodwell DJ. Malignant bone resorption: cellular and biochemical mechanisms. Ann oncol 1992; 3: Powles T et al. Controled trial of clodronate in patient with primary operable breast cancer. J Clin Oncol 2002; 20: Orr F, Lee J, Duivenvoorden WC. Pathophysiologic interactions in skeletal metastasis. Cancer, Suppl 2000; 88: Sansoni P, Passeri G, Fangnoni F. Inhibition of antigen presenting and cell function by alendronate in vitro. J. Bone Miner Res 1995; 10: Lissoni P, Cazzanigna M, Barni, Derenne S. Acute effect of pamidronate administration on serum levels of interleukin-6 in advanced solid tumor patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Eur J Cancer 1992; 33: Diel IJ, Solomayer EF, Costa SD. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: Luckman SP, Huges DE, Loxon FF. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins including Ras. J Bone Miner Res 1998; 13: Adami S, Salvagno G, Guarrera G. Dichloromethylene biphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134: Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165: Dearnaley DP et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: Munoy GR. Bisphosphonates and tumor burden. J Clin Oncol 2002; 20: Smith Jr JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of randomized, prospective, double-blind placebo controlled study. JUrol1989; 141: Jagdev SP et al. Comparison of effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption with metastatic bone disease. Ann Oncol 2001; 12: Ernst DS et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/ predinisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:
Bone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationBone metastases of solid tumors Diagnosis and management by
Bone metastases of solid tumors Diagnosis and management by Dr/RASHA M Abd el Motagaly oncology consultant Nasser institute adult oncology unit 3/27/2010 1 Goals 1- Know the multitude of problem of bone
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationThe role of bisphosphonates in breast and prostate cancers
REVIEW Endocrine-Related Cancer (2004) 11 207 224 The role of bisphosphonates in breast and prostate cancers Janet E Brown, Helen Neville-Webbe and Robert E Coleman Academic Unit of Clinical Oncology,
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationGuidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer
Peterborough City Hospital Department of Urology Guidelines for the Shared Care of Patients on hormonal therapy for Prostate Cancer Hormonal Therapy - How does it work? Prostate Cancer relies on the presence
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationGUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE. November 2007(Amended July 2008)
Yorkshire Palliative Medicine Clinical Guidelines Group GUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE November 2007(Amended July 2008) Authors: Dr Kath Lambert and Dr Liz Brown, on behalf
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationSponsored document from The Lancet Oncology
Sponsored document from The Lancet Oncology Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationBone resorption predicts for skeletal complications in metastatic bone disease
British Journal of Cancer (2003) 89, 2031 2037 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Bone resorption predicts for skeletal complications in metastatic bone disease JE Brown 1, CS Thomson
More informationA Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma Fred Saad, Donald M. Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner,
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationOUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
ISSN: 1312-773X (Online) DOI: 10.5272/jimab.2013191.391 Journal of IMAB - Annual Proceeding (Scientific Papers) 2013, vol. 19, issue 1 OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH
More informationChallenges in the management of metastatic prostate cancer
Oncology 323 Challenges in the management of metastatic prostate cancer A significant number of men with prostate cancer will be elderly. Although some of the issues they face will be the same as their
More informationDevelopment and Complications of Bone Metastases in Men With Prostate Cancer
Development and Complications of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationWhat Lung Cancer Patients Need to Know About Bone Health. A Publication of The Bone and Cancer Foundation
What Lung Cancer Patients Need to Know About Bone Health A Publication of The Bone and Cancer Foundation Contents THIS PUBLICATION PROVIDES IMPORTANT INFORMATION ABOUT THE RELATIONSHIP BETWEEN LUNG CANCER
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationMetastatic Bone Disease in Patients with Solid Tumors Burden of Bone Disease and the Role of Zoledronic Acid
REVIEW Metastatic Bone Disease in Patients with Solid Tumors Burden of Bone Disease and the Role of Zoledronic Acid Vera Hirsh Departments of Medicine and Oncology, McGill University Health Centre, Royal
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationTalib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University
Talib A. Najjar, DMD, MDS, PhD Professor Oral & Maxillofacial Surgery Rutgers University 1 Biochemistry Interaction with Oral & Systemic Diseases Periodontal disease Jaw Bone Necrosis due to Bisphosphonate
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationCommunity care of Prostate Cancer. Shaun Costello Southern Cancer Network
Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationDavid P Dearnaley, Malcolm D Mason, Mahesh K B Parmar, Karen Sanders, Matthew R Sydes
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials David P Dearnaley,
More informationBone Health in the Cancer Patient
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Sacred Encounters Perfect Care Healthiest Communities Why
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationSpinal cord compression as a first presentation of cancer: A case report
J Pain Manage 2013;6(4):319-322 ISSN: 1939-5914 Nova Science Publishers, Inc. Spinal cord compression as a first presentation of cancer: A case report Nicholas Lao, BMSc(C), Michael Poon, MD(C), Marko
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationKey words: Bisphosphonates, guidelines, drug use evaluation, breast cancer
DO PHYSICIA FOLLOW SYSTEMIC TREATMENT AND FUNDING POLICY GUIDELINES? A REVIEW OF BISPHOSPHONATE USE IN PATIENTS WITH BONE METASTASES FROM BREAST CANCER Mark Clemons 1, Katherine Enright 1, Annemarie Cesta
More informationRecent Progress in Management of Advanced Prostate Cancer
Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationA Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer
Yonsei Med J 48(6):1001-1008, 2007 DOI 10.3349/ymj.2007.48.6.1001 A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer Sung Joon Hong, 1 Kang
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationIntroduction. In patients with prostate cancer, disease progression can have serious clinical consequences, such as painful bone
(2005) 8, 194 200 & 2005 Nature Publishing Group All rights reserved 1365-7852/05 $30.00 www.nature.com/pcan Bicalutamide ( Casodex ) 150 mg in addition to standard care in patients with nonmetastatic
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationXgeva. Xgeva (denosumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.18 Subject: Xgeva Page: 1 of 5 Last Review Date: March 16, 2018 Xgeva Description Xgeva (denosumab)
More informationBONEFOS 800 mg. Bonefos adalah obat baru yang terdaftar tahun Informasi di bawah ini merupakan informasi update tahun 2008.
Bonefos adalah obat baru yang terdaftar tahun 2007. Informasi di bawah ini merupakan informasi update tahun 2008. BONEFOS 800 mg Important information, please read carefully! Composition 1 tablet contains
More informationManaging Metastatic Bone Pain: The Role of Bisphosphonates
462 Journal of Pain and Symptom Management Vol. 33 No. 4 April 2007 Review Article Managing Metastatic Bone Pain: The Role of Bisphosphonates Julie Gralow, MD, and Debu Tripathy, MD University of Washington
More informationXgeva. Xgeva (denosumab) Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.18 Subject: Xgeva Page: 1 of 5 Last Review Date: December 3, 2015 Xgeva Description Xgeva (denosumab)
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationPolicy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.
Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate
More informationJanuary Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone pre-docetaxel for asymptomatic/minimally symptomatic metastatic castration resistant prostate cancer Abiraterone pre-docetaxel for patients with asymptomatic
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationWinston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida
Winston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida } none } To develop an understanding of the management of bone metastasis through a multidisciplinary approach } Enable the learner
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Zoledronic acid Therapeutic Area of Trial Breast cancer, prostrate cancer Approved Indication Prevention of skeletal related events
More informationGLOSSARY. This glossary includes definitions for patients who have cancer with bone involvement. New definitions will be added periodically.
GLOSSARY This glossary includes definitions for patients who have cancer with bone involvement. New definitions will be added periodically. For more in-depth information, please refer to the Bone and Cancer
More informationBone health in cancer patients: ESMO Clinical Practice Guidelines
clinical practice guidelines Annals of Oncology 25 (Supplement 3): iii124 iii137, 2014 doi:10.1093/annonc/mdu103 Published online 29 April 2014 clinical practice guidelines Bone health in cancer patients:
More informationZoledronic acid in the management of metastatic bone disease
REVIEW Zoledronic acid in the management of metastatic bone disease Thomas J Polascik Vladimir Mouraviev Duke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC,
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationClinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:
Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationBone Metastases and Osteoporosis
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Bone Metastases and Osteoporosis Bone Metastases Version 2002: Dall / Fersis / Friedrich Version 2003 2009: Bischoff / Böhme
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationIbandronate: Its Role in Metastatic Breast Cancer
Ibandronate: Its Role in Metastatic Breast Cancer David Cameron, a Marie Fallon, a Ingo Diel b a Western General Hospital, Edinburgh, United Kingdom; b Institute for Gynecological Oncology, Mannheim, Germany
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationreviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationOncologist. The. Academia Pharma Intersect: Symptom Management and Supportive Care
The Oncologist Academia Pharma Intersect: Symptom Management and Supportive Care Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases MATTI AAPRO, a FRED SAAD, b LUIS
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationSource of effectiveness data The effectiveness evidence was derived from a single study that was identified from a review of the literature.
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK Guest J F, Clegg J P, Davie A M, McCloskey E Record Status This is a critical
More informationOpinion 1 October 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2014 METASTRON, solution for injection, strontium ( 89 Sr) chloride 1 glass vial of 4 ml (CIP: 34009 558
More information